Tinostamustine

DB15147InvestigationalSmall molecule

Tinostamustine is under investigation in clinical trial NCT03452930 (Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma).

Mechanism: Pharmacologically active on Histone deacetylase
Curator reviewed
Formula / weight: C₁₉H₂₈Cl₂N₄O₂ · 415.36 g/mol (avg)
Code names: EDO-S 101

Resolves to

Compound

UNII29DKI2H2NYCAS1236199-60-2ChEMBLCHEMBL3989941

Structure

InChIKeyGISXTRIGVCKQBX-UHFFFAOYSA-NSMILESCN1C(CCCCCCC(=O)NO)=NC2=CC(=CC=C12)N(CCCl)CCCl

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which companies are running trials of Tinostamustine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account